<DOC>
	<DOCNO>NCT00956813</DOCNO>
	<brief_summary>RATIONALE : Estrogen relieve symptom menopause , also cause growth breast cancer cell . Flaxseed may reduce number hot flash improve mood quality life postmenopausal woman receive estrogen therapy . PURPOSE : This randomized phase III trial study flaxseed see well work treat postmenopausal woman hot flash history breast cancer cancer wish take estrogen therapy .</brief_summary>
	<brief_title>Flaxseed Treating Postmenopausal Women With Hot Flashes Who Have History Breast Cancer Other Cancer Who Do Not Wish Take Estrogen Therapy</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy flaxseed hot flash score woman history breast cancer cancer woman wish take estrogen therapy fear increase risk breast cancer measure daily prospective hot flash diary . - To evaluate side effect profile flaxseed population . - To evaluate effect flaxseed mood ( per Profile Mood States ) broad menopausal symptom ( per MENQOL ) , daily interference hot flash ( per HFRDIS ) , perception benefit ( per Global Impression Change ) . OUTLINE : Patients stratify accord age ( 18-49 year vs ≥ 50 year ) ; treatment tamoxifen citrate , selective estrogen receptor modulators , aromatase inhibitor ( yes v ) ; duration hot flash ( ≤ 9 month vs &gt; 9 month ) ; daily frequency hot flash ( 4-9 v ≥ 10 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral flaxseed form bar similar granola bar daily . - Arm II : Patients receive oral placebo bar daily . In arm , treatment continue 6-12 week . Patients arm II may crossover receive treatment arm I 6 week . Patients complete questionnaire ( Hot Flash Diary , Side Effect Experience Questionnaire , Profile Mood States , Hot Flash Related Daily Interference Scale , Menopause Specific Quality Life ) baseline periodically treatment . Patients contact telephone end week 2 , 4 , 5 , 7 assess product tolerability , document compliance , encourage completion questionnaire , address problem .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Bothersome hot flash , define occurrence ≥ 28 time per week sufficient severity make patient desire therapeutic intervention Presence hot flash ≥ 1 month Meets 1 follow criterion : History breast cancer cancer ( currently without malignant disease ) No history breast cancer wish avoid estrogen due perceive increased risk breast cancer Hormone receptor status specify Postmenopausal define 1 following* : NOTE : *Women ≥ 1 ovary without uterus deem postmenopausal either age &gt; 55 OR combination estrogen within postmenopausal range ( per local lab ) folliclestimulating hormone &gt; 40 mIU/mL Absence period past 12 month Bilateral oophorectomy ECOG performance status 01 Life expectancy ≥ 6 month Able complete questionnaire ( ) alone assistance No diabetes require oral injectable antihyperglycemics No hypotension No history allergic adverse reaction flaxseed No irritable bowel syndrome , colitis , Crohn disease , gastrointestinal condition patient consume and/or intolerance/allergies seed nut At least 4 week since prior concurrent plan androgen , estrogen , progestational agent Tamoxifen , raloxifene , aromatase inhibitor allow provided patient constant dose ≥ 4 week expect stop medication study treatment • At least 4 week since prior concurrent anticancer therapy kind Trastuzumab allow No concurrent treatment anticancer therapy kind except trastuzumab endocrine therapies No concurrent ( ≤ 7 day prior registration ) plan use agent treat hot flash ( i.e. , gabapentin , clonidine , antidepressant , estrogen treatment , megestrol acetate , Bellergal ) Stable dose vitamin E ( general vitamin supplement ) allow provide ≤ 800 IU/day , start &gt; 30 day study initiation , continue study period Patients use antidepressant mood stable dose month meet eligibility criterion hot flash frequency duration eligible • No concurrent anticoagulant antiplatelets ( 1 mg Coumadin central line patency allow ) Aspirin allow ( ≤ 81 mg ) No concurrent antihypertensives No concurrent herbal supplement reason , include soy soy supplement ( i.e. , powder , pill , milk )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>menopausal symptom</keyword>
	<keyword>hot flash</keyword>
	<keyword>breast cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>